E Cannabis Central: These Companies Intend To Become Major Players In Europe

6. OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI) is well positioned in Europe undertaking the following investments:

  • In June 2018 OGI invested $10,000,000 in Serbian-based hemp and CBD producer Eviana Health Corporation (CSE:EHC) for 26% of its outstanding shares on a non-diluted basis (and 40% on a fully diluted basis) to provide Organigram with a source of low-cost, high-quality CBD for the burgeoning medical market within Europe.
  • In October 2018, bought a 25% interest in Stadthagen, Germany company, alpha-cannabis Pharma GmbH (ACG), which is strategically positioned to serve more than 20,000 pharmacies in Germany, Austria and Switzerland.

For a detailed financial analysis please go here.

OrganiGram stock is down 46% since its recent high on May 17th.

7. Tilray Inc. (NASDAQ:TLRY) is making a valiant effort to establish itself as outlined below:

  • On July 23rd Tilray announced the acquisition of United Kingdom-based company, Smith & Sinclair, a developer/producer/marketer of boozy candies, edible fragrances and other unique cocktail treats. The deal gives Tilray a way to develop novel cannabis products as it tries to differentiate themselves and attract new customers and should give a major boost to the company’s efforts to get into the CBD-infused edibles market just in time for the legalization of CBD-infused edibles in Canada at the end of 2019.
  • Earlier this week Tilray's Portuguese subsidiary, Tilray Portugal Unipessoal Lda., signed an agreement with Cannamedical Pharma GmbH to export $3.3 million worth of medical cannabis to Germany this autumn which will give Tilray access to a much larger market than that of its home country of Canada.

For a detailed financial analysis please go here.

Tilray needs a shot in the arm given the performance of its stock which has been terrible this year. As of the close of business on Aug. 26th Tilray's stock was down 72% from its recent high on Feb. 28th.

8. Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB) continues to move forward in cementing its positioning in Europe’s medical cannabis market to ensure that it is ready to enter new markets as regulatory barriers fall and demand rises.

Aurora has more production capacity than any other company with over500,000 kilograms in annual output and, as production ramps up throughout Canada, supply could outpace demand by as early as 2021 and, to sell its domestic excess supply, Aurora is expanding into European markets and, to that end, Aurora:

  • created a European subsidiary, Aurora Europe GmbH, to manage its affairs in Europe with divisions in Germany (Aurora Deutschland GmbH), Poland (Aurora Polska) and Netherland (Aurora Nederland B.V.),
  • entered into a joint venture, back in January, 2018, with Alfred Pedersen & Son for a 51% interest in Aurora Nordic Cannabis A/S, the joint venture company. The company is based in Odense, Denmark and is one of few companies with a license to cultivate in Europe which will make it the continent`s largest producer of cannabis.
    • Aurora Nordic will focus on the cultivation and sales of cannabis in Denmark, Sweden, Norway, Finland and Iceland, through Aurora's wholly-owned subsidiary Pedanios GmbH (a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany) with excess capacity being distributed to other EU countries with the support of Pedanios.
    • According to Terry Booth, CEO of Aurora, the JV has established Aurora as the leading cannabis company in Europe and the leading exporter to, and distributor of, medical cannabis in Germany.
  • won the right through its subsidiary, Aurora Deutschland, to supply Italy (the second-largest European medical cannabis market) with a total of 400 kilograms (880 pounds) of medical marijuana over the next two years,
  • acquired 51% of Gaia Pharm in Portugal, soon to be renamed Aurora Portugal, on the heels of it receiving approval from the EU to construct a cannabis cultivation facility there which is expected to be completed (first phase) in the third calendar quarter of 2020,
  • completed its first commercial export of cannabis oil to the United Kingdom,
  • began construction of an indoor cannabis production facility in Leuna, Germany in May 2019 with completion expected within 12 months and initial shipments of locally grown cannabis expected to become available to German medical patients starting in October 2020.

For a detailed financial analysis please go here.

As of the close of business on Aug. 26th Aurora's stock is down 42% from its recent peak on March 18th, 2019.

9. Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), one of the world’s biggest medical cannabis companies, is making major investments in Europe to expand production there over the next two years with new growing facilities in Italy, Greece or Spain. Specifically, Canopy, through its subsidiary, Spectrum Cannabis has:

View single page >> |
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.